In sum, we demonstrate a higher pre-clinical efficacy with dual HSF-HSP90 pathway inhibition in an autochthonous mouse colonic tumor model in vivo and confirm that in this synergistic context, HSP90 inhibitors are promising cancer drugs with strong tumor selectivity. Here, HSP90AB1 is linked to colonic neoplasm.